Drug Trial Radar · NCT00342355
Antiretroviral Therapy for Advanced HIV Disease in South Africa
Last checked: Nov 19, 2026Latest source record: May 21, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,771
Actual
Start
Jan 2004
Primary completion
Mar 2008
Study completion Aug 2008
Sponsor
- Lead sponsor
- National Institutes of Health Clinical Center (CC)NIH
- Sponsor type
- NIH
- First posted
- Jun 21, 2006
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Factorial
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 14 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will determine how well four different antiretroviral drug therapies work in patients with advanced HIV disease. The trial is part of the South Africa-U.S. Project Phidisa Programme - a collaboration between the South African Military Health Service (SAMHS) of the South African National Defense Force (SANDF), the U.S. Department of Defense, and the U.S. National Institutes of Health - to help prevent HIV transmission among South African military and civilian employees and their families. Members of the SANDF with HIV infection may be eligible for this study. HIV-infected family members who are 14 years of age and older may also participate. All participants must have a CD4 count of less than 200 or an AIDS-defining illness. Participants are randomly assigned to one of the following four antiretroviral drug regimens, which require taking 5 pills or more every day: * AZT (zidovudine) + ddl (didanosine) + EFV (efavirenz) * AZT (zidovudine) + ddl (didanosine) + r/LPV (lopinavir/ritonavir) * D4T (stavudine) + 3TC (lamivudine) + EFV (efavirenz) * D4T (stavudine) + 3TC (lamivudine) + r/LPV (lopinavir/ritonavir) Patients are followed for up to 6 years. Clinic visits are scheduled once a month for the first 3 months and then once every 3 months for the next five years. Patients undergo a medical history, physical examination, and blood tests at each visit, and complete questionnaires of behavior, quality of life, and force readiness every year.
Conditions
- HIV
Interventions
ZidovudineDrug
600 mg once daily
StavudineDrug
40 mg once daily
DidanosineDrug
\<60 kg/125 mg twice daily or \>60kg/200 mg twice daily
LamivudineDrug
300 mg once daily
EfavirenzDrug
600 mg once daily
Lopinavir/RitonavirDrug
r/LPV 400mg/100mg twice daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression to AIDS or Death in tx naïve Pts With Adv HIV dx in the Four Randomly Assigned Regimens.Time frame: January 2004 until March 31 2008
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
South African Military Health Services (SAMHS)
Centurion, South Africa
Umtata Sickbay
Eastaern Cape, South Africa
3 Military Hospital
Free State, South Africa
1 Military Hospital
Gauteng, South Africa
Mtubatuba SIckbay
Kwazulu-Natal, South Africa
Phalaborwa Sickbay
Limpopo, South Africa
2 Military Hospital
Western Cape, South Africa
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.